2023-11-08 16:03:05 ET
More on Lantern Pharma
- Seeking Alpha’s Quant Rating on Lantern Pharma
- Historical earnings data for Lantern Pharma
- Financial information for Lantern Pharma
For further details see:
Lantern Pharma GAAP EPS of -$0.292023-11-08 16:03:05 ET
For further details see:
Lantern Pharma GAAP EPS of -$0.29Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...